Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$9.88 +11.6%	$7.01	$4.77 ▼ $13.73	$561.73M	0.33	187,595 shs	2.32 million shs
BEAM Beam Therapeutics	$20.07 +2.5%	$17.91	$13.53 ▼ $35.25	$1.97B	2.07	1.57 million shs	2.14 million shs
IDYA IDEAYA Biosciences	$22.15 +3.4%	$20.74	$13.45 ▼ $44.42	$1.88B	0.03	989,521 shs	619,586 shs
IRON Disc Medicine	$57.34 +1.9%	$50.78	$30.82 ▼ $68.73	$1.95B	0.76	338,678 shs	422,819 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+0.23%	+14.19%	+26.79%	+40.70%	-35.64%
BEAM Beam Therapeutics	-7.51%	-3.55%	+14.77%	+17.81%	-23.58%
IDYA IDEAYA Biosciences	-5.09%	-0.09%	-3.38%	+32.45%	-48.17%
IRON Disc Medicine	-2.55%	+6.23%	+4.77%	+37.24%	+14.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVX Abivax	2.2388 of 5 stars	3.5	2.0	0.0	2.8	0.8	0.6
BEAM Beam Therapeutics	2.2684 of 5 stars	3.5	0.0	0.0	3.2	2.5	0.6
IDYA IDEAYA Biosciences	3.574 of 5 stars	3.4	1.0	4.4	2.1	1.7	0.0
IRON Disc Medicine	3.1944 of 5 stars	4.5	2.0	0.0	2.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	3.00	Buy	$31.00	213.77% Upside
BEAM Beam Therapeutics	3.00	Buy	$48.75	142.90% Upside
IDYA IDEAYA Biosciences	2.85	Moderate Buy	$47.55	114.65% Upside
IRON Disc Medicine	3.09	Buy	$96.70	68.64% Upside

Current Analyst Ratings Breakdown

Latest ABVX, BEAM, IDYA, and IRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	IDYA IDEAYA Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$25.00
7/9/2025	IDYA IDEAYA Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$57.00 ➝ $30.00
7/3/2025	IRON Disc Medicine	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$85.00
7/3/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
6/26/2025	IDYA IDEAYA Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$44.00
6/26/2025	IDYA IDEAYA Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$44.00
6/17/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
6/16/2025	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
6/11/2025	IRON Disc Medicine	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$89.00
5/22/2025	IDYA IDEAYA Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$63.00 ➝ $66.00
5/12/2025	IRON Disc Medicine	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$112.00 ➝ $120.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$0.69 per share	N/A
BEAM Beam Therapeutics	$63.52M	31.77	N/A	N/A	$8.86 per share	2.27
IDYA IDEAYA Biosciences	$7M	277.13	N/A	N/A	$12.25 per share	1.81
IRON Disc Medicine	N/A	N/A	N/A	N/A	$14.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$190.71M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/11/2025 (Estimated)
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
IDYA IDEAYA Biosciences	-$274.48M	-$3.59	N/A	N/A	N/A	N/A	-29.28%	-27.68%	8/5/2025 (Estimated)
IRON Disc Medicine	-$109.36M	-$3.92	N/A	N/A	N/A	N/A	-22.61%	-21.07%	8/6/2025 (Estimated)

Latest ABVX, BEAM, IDYA, and IRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	ABVX Abivax	-$0.9220	N/A	N/A	N/A	$1.19 million	N/A
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	N/A	N/A	N/A	$13.29 million	N/A
8/5/2025	Q2 2025	IDYA IDEAYA Biosciences	-$0.85	N/A	N/A	N/A	$3.48 million	N/A
5/7/2025	Q1 2025	IRON Disc Medicine	-$0.99	-$1.02	-$0.03	-$1.02	N/A	N/A
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
5/6/2025	Q1 2025	IDYA IDEAYA Biosciences	-$0.75	-$0.82	-$0.07	-$0.82	$2.10 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	1.29	1.25	1.25
BEAM Beam Therapeutics	N/A	8.81	8.81
IDYA IDEAYA Biosciences	N/A	13.92	13.92
IRON Disc Medicine	0.04	37.65	37.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
BEAM Beam Therapeutics	99.68%
IDYA IDEAYA Biosciences	98.29%
IRON Disc Medicine	83.70%

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
BEAM Beam Therapeutics	3.50%
IDYA IDEAYA Biosciences	2.50%
IRON Disc Medicine	4.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	61	63.47 million	N/A	Not Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
IDYA IDEAYA Biosciences	80	87.58 million	85.39 million	Optionable
IRON Disc Medicine	30	34.63 million	33.17 million	Not Optionable

ABVX, BEAM, IDYA, and IRON Headlines

Recent News About These Companies

Disc Medicine, Inc. (NASDAQ:IRON) CFO Sells $115,000.00 in Stock

July 15 at 4:39 AM | insidertrades.com

Disc Medicine, Inc. (NASDAQ:IRON) CFO Jean M. Franchi Sells 2,000 Shares

July 14 at 10:23 PM | marketbeat.com

Disc Medicine, Inc. Appoints Nadim Ahmed to Board of Directors

July 14 at 9:23 AM | quiverquant.comQ

Disc Medicine Appoints Nadim Ahmed to its Board of Directors

July 14 at 8:30 AM | globenewswire.com

Insider Selling: Disc Medicine, Inc. (NASDAQ:IRON) CEO Sells 34,800 Shares of Stock

July 11, 2025 | marketbeat.com

Morgan Stanley Assumes Coverage of Disc Medicine (IRON) With $85 PT

July 10, 2025 | msn.com

Disc Medicine Earns Relative Strength Rating Upgrade; Hits Key Threshold

July 9, 2025 | msn.com

Insider Selling: Disc Medicine, Inc. (NASDAQ:IRON) CEO Sells 5,200 Shares of Stock

July 9, 2025 | insidertrades.com

John D. Quisel Sells 5,200 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

July 8, 2025 | marketbeat.com

Disc Medicine (NASDAQ:IRON) Now Covered by Analysts at Morgan Stanley

July 3, 2025 | marketbeat.com

HC Wainwright Reaffirms Buy Rating for Disc Medicine (NASDAQ:IRON)

July 3, 2025 | marketbeat.com

Disc Medicine Inc Ordinary Shares IRON - Morningstar

July 2, 2025 | morningstar.comM

Disc Medicine, Inc. (NASDAQ:IRON) Given Consensus Rating of "Buy" by Analysts

June 28, 2025 | marketbeat.com

IRON - Disc Medicine Inc Ordinary Shares Ownership - Morningstar

June 27, 2025 | morningstar.comM

Leerink Partners Reiterates a Buy Rating on Disc Medicine (IRON) With an $85 Price Target

June 24, 2025 | msn.com

SG Americas Securities LLC Grows Stake in Disc Medicine, Inc. (NASDAQ:IRON)

June 21, 2025 | marketbeat.com

Jean M. Franchi Sells 2,000 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

June 19, 2025 | insidertrades.com

GAMMA Investing LLC Grows Position in Disc Medicine, Inc. (NASDAQ:IRON)

June 19, 2025 | marketbeat.com

Insider Selling: Disc Medicine, Inc. (NASDAQ:IRON) CFO Sells 2,000 Shares of Stock

June 18, 2025 | marketbeat.com

Lifesci Capital Weighs in on Disc Medicine FY2025 Earnings

June 18, 2025 | marketbeat.com

HC Wainwright Reiterates "Buy" Rating for Disc Medicine (NASDAQ:IRON)

June 17, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVX, BEAM, IDYA, and IRON Company Descriptions

Abivax NASDAQ:ABVX

$9.88 +1.03 (+11.64%)

Closing price 04:00 PM Eastern

Extended Trading

$9.96 +0.08 (+0.81%)

As of 07:01 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Beam Therapeutics NASDAQ:BEAM

$20.07 +0.49 (+2.50%)

Closing price 04:00 PM Eastern

Extended Trading

$20.06 -0.01 (-0.05%)

As of 07:59 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

IDEAYA Biosciences NASDAQ:IDYA

$22.15 +0.72 (+3.36%)

Closing price 04:00 PM Eastern

Extended Trading

$22.56 +0.42 (+1.87%)

As of 07:40 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Disc Medicine NASDAQ:IRON

$57.34 +1.07 (+1.90%)

Closing price 04:00 PM Eastern

Extended Trading

$57.29 -0.05 (-0.09%)

As of 07:00 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time